| Hazard Information | Back Directory | [Uses]
Urtoxazumab (TMA-15) is a humanizedized monoclonal antibody against Shiga toxin (Stx) 2[1]. | [in vivo]
Urtoxazumab (TMA-15) (0.25-2.5 mg/kg; i.v.; once) ameliorates the lethal challenge in a time- and dose- dependent manner in B2F1-infected mice[1]. | Animal Model: | 5-week-old male DBA/2J mice, STEC B2F1-infection model[1] | | Dosage: | 0.25, 0.5, 1.0, 2.0 and 2.5 mg/kg | | Administration: | Intravenous administration, 1 h before and 12, 24, and 48 h after infection | | Result: | Pretreatment completely protected the infected mice from death, the efficacy of the low dose (0.25 mg/kg) was partial when administered at 12 and 24 h after infection, but the efficacy of the high dose (2.5 mg/kg) was still complete. Prevented death from B2F1 infection in all 20 animals at 1.0 and 2.0 mg/kg 24 h after infection. |
| [References]
[1] Yamagami S, et al. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J Infect Dis. 2001 Sep 15;184(6):738-42. DOI:10.1086/323082 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|